Compare DNUT & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNUT | RCKT |
|---|---|---|
| Founded | 1937 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 524.0M | 239.3M |
| IPO Year | 2021 | 2014 |
| Metric | DNUT | RCKT |
|---|---|---|
| Price | $2.87 | $2.20 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 14 |
| Target Price | $4.08 | ★ $8.58 |
| AVG Volume (30 Days) | 1.8M | ★ 2.2M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.37 |
| EPS | N/A | ★ 0.66 |
| Revenue | ★ $1,522,616,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.20 | $915.60 |
| P/E Ratio | ★ N/A | $3.52 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.83 | $2.17 |
| 52 Week High | $4.75 | $5.45 |
| Indicator | DNUT | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 38.89 | 33.80 |
| Support Level | $2.86 | N/A |
| Resistance Level | $3.72 | $3.70 |
| Average True Range (ATR) | 0.11 | 0.17 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 11.43 | 6.50 |
Krispy Kreme Inc is a sweet-treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations world-wide. It derives maximum revenue from the U.S. segment.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.